Skip to search formSkip to main contentSkip to account menu

ABT751

Known as: ABT-751 
An orally bioavailable antimitotic sulfonamide. ABT- 751 binds to the colchicine-binding site on beta-tubulin and inhibits the polymerization of… 
National Institutes of Health

Related topics

Related topics

4 relations
E 7010Microtubule ProcessNCIt Antineoplastic Agent Terminology

Broader (1)

Sulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751
Objective ABT-751, a novel orally available antitubulin agent, is mainly eliminated as inactive glucuronide (ABT-751G) and… 
2012
2012
Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
BACKGROUND ABT-751 is a novel orally available antimitotic agent that targets microtubule polymerization. This mechanism may… 
2007
2007
Evaluation of ABT-751 against childhood cancer models in vivo
SummaryObjectiveABT-751 is a novel antimitotic agent that binds tubulin at the colchicine binding site. ABT-751 is undergoing… 
2006
2006
In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines
4351 ABT-751 is an orally bioavailable sulfonamide that is not a substrate for P-glycoprotein and which binds the colchicine… 
2006
2006
A phase I trial of ABT-751 and carboplatin (C) in patients (pts) with previously treated non-small cell lung cancer (NSCLC).
17098 Background: NSCLC is the leading cause of cancer mortality for men and women in the United States. More effective… 
2005
2005
Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC)
3537 Background: ABT-751, an oral antimitotic agent that binds to the colchicine site of β-tubulin and prevents microtubule… 
2005
2005
Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC)
7137 Background: ABT-751, an oral antimitotic agent that binds to the colchicine site of β-tubulin and prevents microtubule… 
2005
2005
Targeting the unmet medical need: the Abbott Laboratories oncology approach.
While significant advances in the treatment of cancer occured during the last half of the twentieth century, parallel decreases… 
2005
2005
Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC).
4603 Background: There is currently no effective adjuvant therapy available for subjects with advanced RCC. ABT-751, an oral… 
2004
2004
Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors.
2080 Background: ABT-751 is an orally bioavailable sulfonamide that binds to the colchicine-binding site on β-tubulin and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)